SantoSolve (Norway) a clinical-stage biopharmaceutical company focused on topical analgesic products based on non-radioactive strontium for various pain conditions, closed a $5.5M Series C financing. Participants include Teknoinvest, InnovationsKapital and Investinor.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb